BidaskClub lowered shares of Horizon Therapeutics (NASDAQ:HZNP) from a hold rating to a sell rating in a research report sent to investors on Wednesday, BidAskClub reports.
A number of other analysts have also recently issued reports on the company. TheStreet cut Horizon Therapeutics from a b- rating to a c+ rating in a research note on Monday, June 10th. Mizuho set a $27.00 target price on Horizon Therapeutics and gave the stock a hold rating in a research note on Wednesday, May 8th. Citigroup raised Horizon Therapeutics from a neutral rating to a buy rating and increased their target price for the stock from $21.00 to $32.00 in a research note on Wednesday, May 1st. Piper Jaffray Companies set a $33.00 target price on Horizon Therapeutics and gave the stock a buy rating in a research note on Thursday, April 4th. Finally, BMO Capital Markets increased their target price on Horizon Therapeutics to $29.00 and gave the stock a market perform rating in a research note on Thursday, April 4th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $30.83.
NASDAQ HZNP opened at $22.81 on Wednesday. Horizon Therapeutics has a 52-week low of $15.92 and a 52-week high of $29.44. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.74 and a quick ratio of 1.68.
Horizon Therapeutics (NASDAQ:HZNP) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.20. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The business had revenue of $280.00 million during the quarter, compared to analysts’ expectations of $238.35 million. During the same period in the prior year, the business earned $0.03 EPS. Horizon Therapeutics’s revenue for the quarter was up 25.0% compared to the same quarter last year. On average, sell-side analysts forecast that Horizon Therapeutics will post 1.62 EPS for the current fiscal year.
In other news, insider Jeff Kent sold 3,620 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $24.64, for a total transaction of $89,196.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of HZNP. FMR LLC grew its stake in shares of Horizon Therapeutics by 165.1% during the 1st quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock worth $137,575,000 after acquiring an additional 3,242,071 shares in the last quarter. Norges Bank bought a new position in shares of Horizon Therapeutics during the 4th quarter worth approximately $46,493,000. Renaissance Technologies LLC grew its stake in shares of Horizon Therapeutics by 29.5% during the 1st quarter. Renaissance Technologies LLC now owns 7,857,775 shares of the biopharmaceutical company’s stock worth $207,681,000 after acquiring an additional 1,791,500 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of Horizon Therapeutics by 63.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 3,369,508 shares of the biopharmaceutical company’s stock worth $65,840,000 after acquiring an additional 1,312,142 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in shares of Horizon Therapeutics during the 1st quarter worth approximately $27,663,000. 87.79% of the stock is owned by institutional investors.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: How the Consumer Price Index (CPI) is calculated?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.